Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs standard-dose influenza vaccine in adults 50-64 years
NCT06641180Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trivalent influenza vaccine in influenza, sponsored by Sanofi. Started Nov 2024; status: completed.
02
Drugs
trivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06641180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641180.